Literature DB >> 1530661

Analysis of the inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N6-methyladenosine.

I S Vizirianakis1, W Wong, A S Tsiftsoglou.   

Abstract

Treatment of cultured murine erythroleukemia (MEL or Friend) cells with N6-methylated derivatives of adenosine inhibited erythroid cell differentiation induced by various agents. N6-Methyladenosine (N6mAdo) inhibited initiation of commitment to terminal maturation and prevented accumulation of hemoglobin in a concentration-dependent manner. Treatment with N6mAdo slowed cell growth without causing substantial inhibition in the rate of DNA synthesis and a marked decrease in viability and clonogenic potential of MEL cells. Furthermore, N6mAdo decreased the cytoplasmic accumulation of beta(major) globin mRNA and affected its structural integrity in MEL cells. Cells pre-exposed to N6mAdo failed to initiate commitment as early as control cells upon challenge with the inducer dimethyl sulfoxide. N6mAdo-induced inhibition of commitment was not reversed but rather was potentiated by the presence of adenine, L-homocysteine and/or L-methionine, agents involved in the active methylation cycle. To this respect, N6mAdo-induced inhibition of commitment was found to be different from that caused by cordycepin (3'-deoxyadenosine, an inhibitor of RNA methylation and mRNA polyadenylation). The latter inhibition was fully reversed by the addition of L-methionine. These findings indicate that N6-methyladenosine: (a) blocks a central process that is required for initiation of commitment; and (b) decreases accumulation of beta (major) globin mRNA, causes mRNA degradation and prevents hemoglobin synthesis. Due to the differential sensitivity of N6mAdo- and cordycepin-induced blockade of commitment to L-methionine, these agents inhibit commitment by acting via two different mechanisms impinging on the final pathway of MEL erythroid cell maturation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530661     DOI: 10.1016/0006-2952(92)90125-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  miR-16-5p Promotes Erythroid Maturation of Erythroleukemia Cells by Regulating Ribosome Biogenesis.

Authors:  Christos I Papagiannopoulos; Nikoleta F Theodoroula; Ioannis S Vizirianakis
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-09

2.  The histone methyltransferase inhibitor A-366 enhances hemoglobin expression in erythroleukemia cells upon co-exposure with chemical inducers in culture.

Authors:  Christos I Papagiannopoulos; Nikoleta F Theodoroula; Konstantinos A Kyritsis; Melpomeni G Akrivou; Maria Kosmidou; Konstantina Tsouderou; Nikolaos Grigoriadis; Ioannis S Vizirianakis
Journal:  J Biol Res (Thessalon)       Date:  2021-01-06       Impact factor: 1.889

3.  Invariable Ribosome Stoichiometry During Murine Erythroid Differentiation: Implications for Understanding Ribosomopathies.

Authors:  Christos I Papagiannopoulos; Konstantinos A Kyritsis; Konstantina Psatha; Dimitra Mavridou; Fani Chatzopoulou; Georgia Orfanoudaki; Michalis Aivaliotis; Ioannis S Vizirianakis
Journal:  Front Mol Biosci       Date:  2022-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.